After a weak clinical trial result that wiped more than half of Prima BioMed ’s value, chief executive Matthew Lehman is pinning his hopes on a smaller group of patients who responded positively to the company’s ovarian cancer therapy.
At least one analyst has described the revised strategy as risky, but Mr Lehman is upbeat.
Loading...
Jessica Gardner is Deputy editor - News. She has previously edited the Companies and Markets section. Connect with Jessica on Twitter. Email Jessica at jgardner@afr.com
